ZBHZimmer Biomet

$101.36

The financials

Zimmer Biomet by the numbers

Zimmer Biomet (ZBH) reported revenue of $2.09B in Q1 2026 (quarter ended March 31, 2026), up 9.3% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $238M (11% of revenue). For the full year FY2025, revenue was $8.23B (+7.2% year on year) and net income $705M. Its largest product in 2026-Q1 was Knees at $829M, 40% of the disclosed total, just ahead of SET at 27%.

Zimmer Biomet income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$2.09B$1.91B+9.3%
Gross profit$1.51B$1.36B+11%
Operating income$373M$292M+28%
Net income$238M$182M+31%
Diluted EPS$1.22$0.91+34%
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Knees$829M40%
SET$562M27%
Hips$524M25%
Technology And Data Bone Cement And Surgical$172M8.2%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $2.09B (+4.3%)
SET grew +19% year on yearKnees +4.5% year on year
  • Knees$828.6MQoQ +4.6%year on year +4.5%
  • SET$562.2MQoQ +3.8%year on year +19%
  • Hips$524.1MQoQ +3.5%year on year +5.7%
  • Technology And Data Bone Cement And Surgical$171.8MQoQ +6.5%year on year +15%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-01, SEC EDGAR